Good news for people newly diagnosed with rare autoimmune disorder: Study finds low relapse risk

A Kaiser Permanente study published in Neurology suggests that patients diagnosed with MOGAD, a rare autoimmune disorder, have a higher likelihood of full recovery and lower relapse risk than previously estimated. The findings offer a more optimistic prognosis for those newly diagnosed.
Why it matters
This research provides critical medical clarity for patients facing a frightening diagnosis, potentially reducing anxiety and guiding treatment decisions.
edited by Gaby Clark , reviewed by Andrew Zinin
This article has been reviewed according to Science X's editorial process and policies . Editors have highlighted the following attributes while ensuring the content's credibility:
Add to Preferred Sources Credit: Unsplash/CC0 Public Domain People newly diagnosed with myelin oligodendrocyte glycoprotein antibody-associated disease, or MOGAD, generally had a low risk of relapse and lasting disability, according to a Kaiser Permanente study. The work is published in the journal Neurology .
Researchers from Kaiser Permanente in Southern California followed 69 children and adults diagnosed at their first MOGAD attack and found that more than 80% fully recovered, while just under 12% experienced a relapse during a median follow-up of about 32 months. MOGAD is a rare inflammatory disease of the central nervous system that can affect the brain, spinal cord and optic nerves and cause severe neurological symptoms.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in